Trilogy Capital Inc. Purchases 50 Shares of Cencora, Inc. (NYSE:COR)

Trilogy Capital Inc. increased its position in shares of Cencora, Inc. (NYSE:COR) by 5.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,038 shares of the company’s stock after buying an additional 50 shares during the quarter. Trilogy Capital Inc.’s holdings in Cencora were worth $233,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Czech National Bank lifted its holdings in shares of Cencora by 12.6% in the 3rd quarter. Czech National Bank now owns 35,536 shares of the company’s stock worth $7,998,000 after purchasing an additional 3,990 shares in the last quarter. Dynamic Advisor Solutions LLC raised its holdings in Cencora by 15.2% during the third quarter. Dynamic Advisor Solutions LLC now owns 1,166 shares of the company’s stock worth $262,000 after buying an additional 154 shares during the last quarter. Tobam lifted its stake in shares of Cencora by 85.7% in the third quarter. Tobam now owns 25,030 shares of the company’s stock valued at $5,634,000 after buying an additional 11,549 shares in the last quarter. LVW Advisors LLC grew its holdings in shares of Cencora by 14.2% during the third quarter. LVW Advisors LLC now owns 3,666 shares of the company’s stock valued at $825,000 after buying an additional 456 shares during the last quarter. Finally, Iowa State Bank bought a new stake in shares of Cencora during the third quarter worth about $1,390,000. Institutional investors own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. UBS Group lifted their price target on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Robert W. Baird lifted their target price on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Wells Fargo & Company increased their price target on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 29th. Barclays lifted their price objective on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Finally, JPMorgan Chase & Co. increased their target price on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and a consensus price target of $277.90.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the sale, the chairman now directly owns 306,752 shares in the company, valued at approximately $74,283,064.32. This represents a 6.55 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the transaction, the executive vice president now owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 73,187 shares of company stock worth $17,790,912. 10.80% of the stock is owned by company insiders.

Cencora Stock Performance

NYSE COR opened at $246.11 on Friday. The company has a market capitalization of $47.57 billion, a PE ratio of 32.77, a price-to-earnings-growth ratio of 1.59 and a beta of 0.49. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $262.26. The company has a 50-day simple moving average of $239.08 and a 200 day simple moving average of $236.51.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.51% and a return on equity of 266.62%. On average, research analysts predict that Cencora, Inc. will post 15.32 EPS for the current year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be given a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.89%. Cencora’s dividend payout ratio is presently 29.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.